Sara A. Hurvitz, MD, on HR-Positive, HER2-Negative Breast Cancer: Results of the neoMONARCH Trial
2016 San Antonio Breast Cancer SymposiumSara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses findings on the biological effects of abemaciclib in a neoadjuvant study for postmenopausal patients (Abstract S4-06).
Related Videos
Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results
Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and brea...
Anne Hudson Blaes, MD, on Aromatase Inhibitors and Cardiovascular Disease
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial
Aleix Prat, MD, PhD, of the University of Barcelona, discusses study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 block...
Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective
Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data ...
Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)
Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual...
